Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Form 144 filing for CeriBell, Inc. (symbol: CBLL) discloses that an affiliate, Xingjuan Chao, plans to sell up to 25,000 common shares through Fidelity Brokerage Services. The proposed sale, valued at $470,000, represents roughly 0.07 % of the 36.14 million shares outstanding and is expected to occur on or about 07 July 2025 on the NASDAQ exchange.
The shares stem from an employee option granted on 07 July 2021 and exercised for cash on the same date as the planned sale. During the previous three months, the same seller executed six separate transactions totaling 75,000 shares and generating ≈ $1.23 million in gross proceeds.
No additional financial statements, earnings figures, or corporate actions are included in this filing. The document is limited to the proposed share sale details required under SEC Rule 144.